Showing 621-640 of 644 for: Cochrane Systematic Reviews > Respiratory 
- Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis
Cochrane Systematic Reviews, 23-Aug-2015
Chronic pulmonary infection in cystic fibrosis results in progressive lung damage. Once colonisation of the lungs with Pseudomonas aeruginosa occurs, it is almost impossible to eradicate. Vaccines, aimed at reducing infection with Pseudomonas aeruginosa,
- Vaccines for preventing influenza in healthy adults
Cochrane Systematic Reviews, 1-Feb-2018
The consequences of influenza in adults are mainly time off work. Vaccination of pregnant women is recommended internationally. This is an update of a review published in 2014. Future updates of this review will be made only when new trials or vaccines be
- Vaccines for preventing influenza in healthy children
Cochrane Systematic Reviews, 1-Feb-2018
The consequences of influenza in children and adults are mainly absenteeism from school and work. However, the risk of complications is greatest in children and people over 65 years of age. This is an update of a review published in 2011. Future updates o
- Vaccines for preventing influenza in people with asthma
Cochrane Systematic Reviews, 28-Feb-2013
Influenza vaccination is recommended for asthmatic patients in many countries as observational studies have shown that influenza infection can be associated with asthma exacerbations. However, influenza vaccination has the potential to cause wheezing and
- Vaccines for preventing influenza in people with cystic fibrosis
Cochrane Systematic Reviews, 6-Mar-2014
Viral respiratory tract infections in people with cystic fibrosis have a deteriorating effect on their lung function and disease progression. Annual influenza vaccination is therefore commonly recommended for people with cystic fibrosis.
- Vaccines for preventing influenza in the elderly
Cochrane Systematic Reviews, 1-Feb-2018
The consequences of influenza in the elderly (those age 65 years or older) are complications, hospitalisations, and death. The primary goal of influenza vaccination in the elderly is to reduce the risk of death among people who are most vulnerable. This i
- Vaccines for preventing pneumococcal infection in adults
Cochrane Systematic Reviews, 31-Jan-2013
Diseases caused by Streptococcus pneumoniae (S. pneumoniae) continue to cause substantial morbidity and mortality globally. Whilst pneumococcal polysaccharide vaccines (PPVs) have the potential to prevent disease and death, the degree of protection afford
- Vagus nerve stimulation for focal seizures
Cochrane Systematic Reviews, 14-Jul-2022
This is an updated version of the Cochrane Review published in 2015.
- Vasoactive drugs for acute stroke
Cochrane Systematic Reviews, 7-Jul-2010
It is unclear whether blood pressure (BP) should be altered actively during the acute phase of stroke.
- Vena caval filters for the prevention of pulmonary embolism
Cochrane Systematic Reviews, 7-Oct-2020
Pulmonary emboli (PE), or blood clots in the lungs,can be potentially fatal. Anticoagulation is the first line therapy to prevent PE. In some instances anticoagulation fails to prevent more emboli, or cannot be given because the person has a high risk of
- Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period
Cochrane Systematic Reviews, 29-Mar-2021
Venous thromboembolism (VTE), although rare, is a major cause of maternal mortality and morbidity. Some women are at increased risk of VTE during pregnancy and the early postnatal period (e.g. caesarean section, family history of VTE, or thrombophilia), a
- Vitamin A and beta (β)‐carotene supplementation for cystic fibrosis
Cochrane Systematic Reviews, 9-Aug-2018
People with cystic fibrosis (CF) and pancreatic insufficiency are at risk of a deficiency in fat-soluble vitamins, including vitamin A. Vitamin A deficiency predominantly causes eye and skin problems, while excessive levels of vitamin A can harm the respi
- Vitamin A for non‐measles pneumonia in children
Cochrane Systematic Reviews, 20-Jul-2005
Acute respiratory infections, mostly in the form of pneumonia, are the leading causes of death in children under five years of age in low-income countries. Some clinical trials have demonstrated that vitamin A supplementation reduces the severity of respi
- Vitamin A for preventing acute lower respiratory tract infections in children up to seven years of age
Cochrane Systematic Reviews, 5-Dec-2010
Vitamin A supplements are effective for preventing diarrhoea. There are theoretical reasons why they may also be effective for acute lower respiratory tract infections (LRTIs), also very common in children, especially in low-income countries.
- Vitamin C for preventing and treating pneumonia
Cochrane Systematic Reviews, 8-Aug-2013
Pneumonia is one of the most common serious infections, causing two million deaths annually among young children in low-income countries. In high-income countries pneumonia is most significantly a problem of the elderly.
- Vitamin C for preventing and treating the common cold
Cochrane Systematic Reviews, 31-Jan-2013
Vitamin C (ascorbic acid) for preventing and treating the common cold has been a subject of controversy for 70 years.
- Vitamin C supplementation for asthma
Cochrane Systematic Reviews, 29-Oct-2018
Vitamin C is one of the key antioxidant vitamins which is abundant in the extracellular fluid lining the lung and low vitamin C intake has been associated with pulmonary dysfunction.
- Vitamin D supplementation for cystic fibrosis
Cochrane Systematic Reviews, 14-May-2014
Cystic fibrosis (CF) is a genetic disorder with multiorgan effects. In a subgroup with pancreatic insufficiency malabsorption of the fat soluble vitamins (A, D, E, K) may occur. Vitamin D is involved in calcium homeostasis and bone mineralisation and may
- Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism
Cochrane Systematic Reviews, 24-Jul-2017
People with venous thromboembolism (VTE) generally are treated for five days with intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin (LMWH), followed by three months of vitamin K antagonists (VKAs). Treatment with VKAs require
- Volume‐targeted versus pressure‐limited ventilation in neonates
Cochrane Systematic Reviews, 17-Oct-2017
Damage caused by lung overdistension (volutrauma) has been implicated in the development of bronchopulmonary dysplasia (BPD). Modern neonatal ventilation modes can target a set tidal volume as an alternative to traditional pressure-limited ventilation (PL
